BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -19.53% | 161.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -19.53% | 161.22% | |||
| Cost of Revenue | 784.38% | 190.91% | |||
| Gross Profit | -134.38% | 157.47% | |||
| SG&A Expenses | 88.99% | -29.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.03% | -25.43% | |||
| Operating Income | 0.57% | 26.74% | |||
| Income Before Tax | -1.16% | 59.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.16% | 59.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.16% | 59.42% | |||
| EBIT | 0.57% | 26.74% | |||
| EBITDA | 0.42% | 26.87% | |||
| EPS Basic | 6.20% | 73.64% | |||
| Normalized Basic EPS | 6.19% | 73.48% | |||
| EPS Diluted | 6.20% | 73.64% | |||
| Normalized Diluted EPS | 6.19% | 73.48% | |||
| Average Basic Shares Outstanding | 7.85% | 53.96% | |||
| Average Diluted Shares Outstanding | 7.85% | 53.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||